Optimization of Quantitative Dynamic Postgadolinium MRI Technique Using Normalized Ratios for the Evaluation of Temporomandibular Joint Synovitis in Patients with Juvenile Idiopathic Arthritis

P. Caruso, K. Buch, S. Rincon, R. Hakimelahi, Z.S. Peacock, C.M. Resnick, C. Foster, L. Guidoboni, T. Donahue, R. Macdonald, H. Rothermel, H.D. Curtin, and L.B. Kaban

ABSTRACT

BACKGROUND AND PURPOSE: MR imaging has been shown to be useful in the diagnosis of juvenile idiopathic arthritis of the temporomandibular joint. Prior MR imaging approaches have relied mainly on the subjective interpretation of synovial enhancement as a marker for synovial inflammation. Although, more recently, several attempts have been made to quantify synovial enhancement, these methods have not taken into account the dynamic enhancement characteristics of the temporomandibular joint and the effect of sampling time. Our aim was to develop a clinically feasible, reproducible, dynamic, contrast-enhanced MR imaging technique for the quantitative assessment of temporomandibular joint synovitis in patients with juvenile idiopathic arthritis and to study the effect of sampling time on the evaluation of synovitis.

MATERIALS AND METHODS: This was a retrospective study of all patients who had dynamic, contrast-enhanced coronal T1 3T MR imaging through the temporomandibular joint at our institution between January 1, 2015, and July 8, 2016. Patients in this cohort included those with a history of juvenile idiopathic arthritis and control patients who underwent MR imaging for other routine, clinical purposes. Synovial enhancement was calculated for each temporomandibular joint using 3 different types of equations termed normalization ratios. The enhancement profiles generated by each equation were studied to determine which provided the best discrimination between affected and unaffected joints, was the least susceptible to sampling errors, and was the most clinically feasible.

RESULTS: A ratio of synovial enhancement (defined as the difference between the postgadolinium and the pregadolinium T1 signal of the longus capitis) provided the best discrimination between affected and unaffected joints, the least susceptibility to sampling error, and was thought to be the most clinically feasible method of quantification of synovial inflammation. Additional synovial enhancement ratios studied did not provide the same level of discrimination between the affected and unaffected joints and were thought to be too temporally variable to provide reliable clinical use.

CONCLUSIONS: We provide a robust, reproducible, dynamic gadolinium-enhanced MR imaging technique for the quantitative assessment of temporomandibular joint synovitis in patients with juvenile idiopathic arthritis.

ABBREVIATIONS: JIA = juvenile idiopathic arthritis; LC = longus capitis; NR = normalization ratio; TMJ = temporomandibular joint

The International League of Associations for Rheumatology defines juvenile idiopathic arthritis (JIA) as an arthritis of unknown etiology that begins before the sixteenth birthday and lasts for a minimum of 6 weeks. The incidence of JIA is estimated at 10.3/100,000. The temporomandibular joint (TMJ) is frequently involved in JIA; TMJ involvement in patients with JIA occurs in 17%–87% of patients.

MR imaging has been shown to be useful in the diagnosis of JIA of the TMJ. While many prior MR imaging approaches have relied on subjective interpretation of synovial enhancement more recently, attempts have been made to assess the utility of quantitative analysis of TMJ synovial enhancements. Peacock et al defined a ratio of the TMJ synovial postgadolinium signal inten-
Table 1: Dynamic gadolinium MRI technique for imaging of the TMJ

| Parameters                        | Details                                                                 |
|-----------------------------------|-------------------------------------------------------------------------|
| Sequence                          | Coronal T1 postgadolinium, 70-sec, 10-sec prescan                      |
| TR/TE (ms)                        | 400/15                                                                  |
| Frequency × phase                 | 300 × 200                                                               |
| NEX                               | 1                                                                      |
| Section thickness                 | 3 mm, 0-mm gap                                                          |
| FOV                               | 14–16 cm                                                               |
| Timing of the serial runs         | Runs: run 0, pregadolinium run, followed by 10 postgadolinum runs with the following timing intervals: run 1: 0–1 min 10 sec; run 2: 1 min 20 sec to 2 min 30 sec; run 3: 2 min 40 sec to 3 min 50 sec; run 4: 4 min 00 sec to 5 min 10 sec; run 5: 5 min 20 sec to 6 min 30 sec; run 6: 6 min 40 sec to 7 min 50 sec; run 7: 8 min 00 sec to 9 min 10 sec; run 8: 9 min 20 sec to 10 min 30 sec; run 9: 10 min 40 sec to 11 min 50 sec; run 10: 12 min 00 sec to 13 min 10 sec |
| Injection technique               | Standard supine position                                                |
| Contrast agent and dosing         | 22-ga angiocatheter in right antecubital fossa, attached to 20-cm length of standard tubing connected to a power injector |
|                                   | Gadoterate meglumine (Dotarem) maintained at room temperature was drawn up at a dose of 0.2 mL/kg (0.1 mmol/kg) of body weight |
|                                   | Simultaneous with the start of the first coronal T1 dynamic sequence, run 1, gadoterate was administered by power injector as a single intravenous bolus injection at a flow rate of 2.5 mL/s followed by a 20-mL saline chaser at the same injection rate |

* Guerbet, Aulnay-sous-Bois, France.

sity normalized to the longus capitis muscle in control patients and found a 95% specificity threshold of 1.55. Resnick et al found that the 1.55 threshold had a 91% sensitivity and 96% specificity for detecting synovitis in symptomatic JIA TMJs. These results, however, rely on measurements of synovial enhancement at a single time point that may not reflect the dynamic contrast enhancement of the TMJ synovia and do not take into consideration the effect of sampling time. The purpose of our study was to establish a reproducible, practical technique for the study of dynamic enhancement curves of the TMJ in patients with JIA and in controls and to determine the effect of sampling time.

**MATERIALS AND METHODS**

**Study Design**

This is an institutional review board–approved, retrospective study in patients who had dynamic contrast-enhanced MR imaging through the TMJ at our institution between January 1, 2015, and July 8, 2016. The dynamic contrast-enhanced technique used in this study was performed on all TMJ MRIs for patients with JIA and for some patients with neuroendocrine MRIs who served as controls.

Patients 18 years of age or younger who underwent dynamic contrast-enhanced MR imaging through the TMJ and longus capitis muscles were included. For controls, only patients in whom dynamic coronal T1 sequences included both the TMJ and the longus capitis muscle (and the target sella turcica) were included.

Exclusion criteria included a history of mandibular/facial trauma, jaw/neck tumor, craniofacial malformation, prior radiation, chemotherapy, or vasculopathy. For controls, additional exclusion criteria included any history of jaw findings: pain, limited range of motion, clicking, mandibular asymmetry, or retrognathia. Any study with artifact that compromised interpretation of the images was excluded.

**Clinical Data**

For patients with JIA, electronic medical records were reviewed for sex; International League of Associations for Rheumatology classification; age at the time of JIA diagnosis, at first presentation with TMJ findings, and at time of MR imaging; TMJ findings including limitation of jaw opening, pain, mandibular asymmetry, retrognathia, bilateral/unilateral TMJ involvement, presence of TMJ symptoms at MR imaging; and medication history, as described in On-line Tables 1 and 2.

For control patients, electronic medical records were reviewed for sex, age at MR imaging, indications for MR imaging, and use of any immunosuppressants within 3 months of MR imaging, as listed in On-line Table 3.

**Imaging Technique**

MRIs were performed on 2 platforms, either a Tim Trio 3T (Siemens, Erlangen, Germany) using a 32-channel head coil or a Discovery MR750 3T (GE Healthcare, Milwaukee, Wisconsin) using an 8-channel head coil. Details of the MR dynamic imaging technique are shown in Table 1.

**Normalized Ratios**

Measurements of the TMJ synovial signal were performed as follows: Ten 0.5-mm² ROIs were measured over each TMJ on the precontrast sequence, 5 over the superior joint compartment and 5 over the lower joint compartment where the measurements were distributed in a standard fashion from lateral to medial across the joint (Fig 1). Ten 0.5-mm² ROIs were then measured similarly over each TMJ on each of the 10 postgadolinium runs for a total of 100 postgadolinium measurements per joint (Fig 1). This technique resulted in 110 measurements per joint (100 postgadolinium + 10 pregadolinium) and 220 measurements per patient (Fig 1).

We then defined 3 distinct quantitative measures of synovial inflammation that we normalized to an internal structure (the longus capitis muscles) to allow for comparison across different patients and time points, ER1, ER2, and R, that we termed collectively “normalized ratios”. ER1 = (postgadolinium T1 signal of the TMJ synovium – the pregadolinium T1 signal of the TMJ synovium) divided by the (postgadolinium T1 signal of the longus capitis – the pregadolinium T1 signal of the longus capitis) where ER1 thus represents the ratio of the enhancement of the TMJ
FIG 1. A and B. Coronal scanning plane and ROI-based measurements of the TMJ synovia. An oblique coronal plane was prescribed off the sagittal localizer to include the entire right and left TMJs and the longus capitis in the same coronal FOV. The coronal plane was angled superoanterior to posteroinferior to include both the TMJs from anterior to posterior and the longus capitis muscle; in controls, the oblique coronal plane included both TMJs, the longus capitis, and the sella turcica. C. An example of a single ROI at the supromedial synovial edge of the right TMJ (0.5 mm²) on a precontrast MR imaging and a single ROI placed along the longus capitis muscle (50 mm²), which was used for normalization. D. Example of the 10 ROIs placed on a postgadolinium MR imaging. These ROIs are placed along the superior and inferior synovial compartments of the left TMJ with the following designations: SL indicates superior compartment, lateral edge; SML, superior compartment, midlateral edge; SC, superior compartment, central; SMM, superior compartment, midmedial edge; SM, superior compartment, medial edge; IL, inferior compartment, lateral edge; IML, inferior compartment, midlateral edge; IC, inferior compartment, central; IMM, inferior compartment, midmedial edge; IM, inferior compartment, medial edge. Although attempts were made to measure the signal along the area closest to the disk edge in the expected location of the synovium, these measurements undoubtedly reflect a composite of signal produced by the synovium, cartilage, and perhaps the periosteum. Thus, the notion of “synovial signal” used in this report reflects this currently unavoidable composite measurement.

Table 2: Measurements of signal intensity over the synovium and longus capitis muscles and calculation of the normalized ratios ER1, ER2, and R

| Calculations                                                                 |
|------------------------------------------------------------------------------|
| Synovial signal intensity                                                    |
| Pre = (SL + SML + SC + SMM + SM + IL + IML + IC + IMM + IM)/10, where, Pre = average precontrast synovial T1 signal intensity measured at 10 points along the synovia |
| Postn = (SL + SML + SC + SMM + SM + IL + IML + IC + IMM + IM)/10, where, Postn = average postgadolinium synovial signal, for run n (n = 1–10) measured at 10 points along the synovia |
| Synovial enhancement = Postn − Pre, for each run n (n = 1–10)                |
| Longus capitis intensity                                                     |
| LCPOSTn = postcontrast T1 signal in the longus capitis, for run n (n = 1–10) |
| Longus capitis enhancement = LCPOSTn − LC PRE, for each run n (n = 1–10)     |
| Normalized ratios                                                            |
| ER1 = (postgadolinium T1 signal of the TMJ synovium − the pregadolinium T1 signal of the TMJ synovium) divided by the (postgadolinium T1 signal of the longus capitis − the pregadolinium T1 signal of the longus capitis) where ER1 thus represents the ratio of the synovial enhancement, to the longus capitis enhancement, for each run n |
| ER2 = (postgadolinium T1 signal of the TMJ synovium − the pregadolinium T1 signal of the TMJ synovium) divided by the (postgadolinium T1 signal of the longus capitis where ER2 thus represents the ratio of the synovial enhancement, to the LCPOST, for each run n |
| R = the postgadolinium T1 signal of the TMJ synovium divided by the postgadolinium T1 signal of the longus capitis and thus represents the ratio of Postn to LCPOST, for each run n |

Note: n indicates each run; SL, superior compartment, lateral edge; SML, superior compartment, midlateral edge; SC, superior compartment, central; SMM, superior compartment, midmedial edge; SM, superior compartment, medial edge; IL, inferior compartment, lateral edge; IML, inferior compartment, midlateral edge; IC, inferior compartment, central; IMM, inferior compartment, midmedial edge; IM, inferior compartment, medial edge; LC POSTn, the measurement of the T1 signal in the longus capitis muscle on the coronal pregadolinium T1 sequence; LCPOSTn, the measurement of the T1 signal in the longus capitis on the postgadolinium coronal T1 sequence for runs 1–10.

The enhancement of the TMJ synovium to the enhancement of the longus capitis. ER2 = (postgadolinium T1 signal of the TMJ synovium − the pregadolinium T1 signal of the TMJ synovium) divided by the postgadolinium T1 signal of the longus capitis where ER2 thus represents the ratio of the enhancement of the TMJ synovium to the postgadolinium T1 signal of the longus capitis. R = the postgadolinium T1 signal of the TMJ synovium divided by the postgadolinium T1 signal of the longus capitis and thus represents a ratio of postgadolinium signals. R is not a true “enhancement” ratio as measures of enhancement require a subtraction of pregadolinium signal from postgadolinium signal that is incorporated into ER1 and ER2 but not into R (Table 2). Then, the individual and average values for ER1, ER2, and R were plotted over the entire 13-minute 10-second sampling period for each patient, for each joint, and at each time point, to yield dynamic normalized ratio profiles.

The joints were then organized into 3 groups: 1) symptomatic joints in patients with JIA, 2) asymptomatic joints in patients with JIA, and 3) controls.

Peak, time to peak, and minimums for ER1, ER2, R, were plotted over the 13-minute 10-second sampling period for each joint.

The ER1s, ER2s, and Rs for each joint were grouped into 0 minute 00 seconds to 3 minutes 50 seconds; 4 minutes 00 seconds to 7 minutes 50 seconds; and 8 minutes 00 seconds to 12 minutes 10 seconds minute intervals and averaged for each joint over these
sampling intervals. The average rate of change of ER1, ER2, and R for each sampling period was determined for symptomatic JIA, asymptomatic JIA, and control joints.

R, the ratio of the postgadolinium T1 signal of the synovium to the postgadolinium T1 signal of the longus capitis, (one of the 3 normalized ratios used in this study), corresponds to the ratio previously published by Resnick et al.6 In these publications, a 1.55 threshold was proposed as a reliable discriminator between symptomatic JIA and control joints. For each temporal sampling point, the relation of R, above or below, to the threshold value 0.95, above or below, was recorded.

Similarly, for ER2, the relation of each sampling point, to a threshold value 0.95, above or below, was recorded.

**Longus Capitis T1 Signal Measurements**
The raw, non-normalized T1 signal from the longus capitis muscle was recorded on the pregadolinium T1 sequence and at each postgadolinium time point for the JIA and control patients.

**Interrater Agreement**
Measurements of synovial T1 signal intensity and the longus capitis were performed independently by 2 raters (K.B., a second-year neuroradiology fellow, and P.C., an attending neuroradiologist with 15 years of head and neck radiology experience).

In 10 joints, each at a different time points, both readers independently measured the lateral edge, center, and medial edge of either the superior or the inferior joint compartment. Thus, 30 ROIs were measured independently by both readers. Interrater agreement was calculated with a κ score.

**Statistics**
A Mann-Whitney U test was used to compare differences among symptomatic, asymptomatic, and control joints for the ER1 and ER2 equations among asymptomatic JIA and control joints, symptomatic JIA and asymptomatic JIA joints, and symptomatic JIA and control joints. These comparisons were made at each of the 10 postgadolinium sampling points.

Calculations were performed using MedCalc statistical software, Version 16.8.4 (MedCalc Software, Mariakerke, Belgium). A 2-tailed t test was used to evaluate differences in raw, non-normalized, average values of the longus capitis among the 3 clinical groups.

### RESULTS

**Study Design**
Eight patients (1 male, 7 females) with JIA (16 joints) and 4 (1 male, 3 females) control patients (8 joints) were included in this study.

**Clinical Data**
The clinical data for the patients with JIA and control group are shown in On-line Tables 1–3.

The average age at MR imaging of the JIA group was 16.1 ± 7.9 years (range, 7.1–33.3 years). The average age at MR imaging of the control group was 15.5 ± 3.7 years (range, 10–18 years). Seven of 8 patients with JIA had been treated with some type of anti-inflammatory agent, and 5 had undergone intra-articular steroid injection before MR imaging.

#### Asymptomatic JIA versus Control Joints

Significant differences in ER1 were noted between these 2 groups at the third postgadolinium time point (P = .03); however, ER1 values at the remaining postgadolinium time points did not demonstrate a statistically significant difference (P = .10–.88).

#### Symptomatic JIA versus Control Joints

Statistically significant differences in ER1 were noted between these 2 groups at all postgadolinium time points (P < .001–.04).

#### Asymptomatic JIA versus Symptomatic JIA Joints

A statistically significant difference in ER1 between these 2 groups for the eighth postgadolinium time point (P = .009) was noted. Otherwise, no statistically significant difference between synovial enhancement ratios at the remaining postgadolinium time points (P = .08–.36) was seen.

### Comparison of Synovial Enhancement Using the ER1 Equation

#### Asymptomatic JIA versus Control Joints

No significant difference was observed for ER2 at all postgadolinium time points be-
tween these 2 groups ($P = .06–1.0$). Of note, the third postgadolinium time point trended toward significance with $P/H_1 < .06$.

**Symptomatic JIA versus Control Joints.** Significant differences were seen at all postgadolinium time points except for the first postgadolinium time point ($P = .01, .03, .01, .001–.006$). If a joint is classified as symptomatic at the first postgadolinium time point, then the next three postgadolinium time points should be classified as asymptomatic.

**Asymptomatic JIA versus Symptomatic JIA Joints.** Significant differences were seen at later postgadolinium time points, between 9 minutes 20 seconds and 13 minutes 10 seconds ($P = .01, .03, .01, .001–.006$). If a joint is classified as asymptomatic at the first postgadolinium time point, then the next three postgadolinium time points should be classified as symptomatic.

**DISCUSSION**

We propose the current study as an illustration of a rigorous technique for quantification of TMJ synovial inflammation in patients with JIA. The technique was controlled for hardware, sequences, injection technique, scan plane, mouth position, and timing of the postgadolinium images. We used 3T platforms with either 32-
Our results show that synovial enhancement curves for patients with JIA are, on average, notably temporally dependent so that technical variations in the acquisition of postgadolinium sequences can place the interpretation at risk of misclassification of a joint, underestimate degree of synovial inflammation, and, over serial scans, compromise evaluation of the response to treatment.

We used 5 separate ROIs spaced evenly across the TMJ in the coronal plane to sample synovial enhancement. The ROI-based assessment performed in this study using a small, 0.5-mm² sampling area minimizes contamination of T1 signal intensity from the intra-articular disk. We found that 5 separate ROI measurements were associated with a good interrater agreement. We think that the inclusion of both TMJ in the same dynamic run. A joint, underestimate degree of synovial inflammation, and, over serial scans, compromise evaluation of the response to treatment.

Our results show that synovial enhancement curves for patients with JIA are, on average, notably temporally dependent so that technical variations in the acquisition of postgadolinium sequences can place the interpretation at risk of misclassification of a joint, underestimate degree of synovial inflammation, and, over serial scans, compromise evaluation of the response to treatment.

Our results show the longus capitis muscle to be an excellent candidate for normalization. No significant difference was seen between enhancement of the longus capitis muscle in JIA and control patients, and the longus capitis demonstrates a long postinjection temporal signal plateau. Synovial TMJ postcontrast T1 signal depends on multiple technical parameters, including magnet strength, scanner platform, TR/TE parameters and injection technique, patient hemodynamics, and intrinsic T1 signal intensity of the TMJ synovium. Because of these variations in both technical and physiologic parameters, it is important to adopt a method for normalizing the quantitative measurements of the synovium to allow comparisons between scans performed on different patients and at different time points. Prior publications have chosen different normalization ratios, normalizing to the same joint or normalizing by the signal-to-noise ratio. The longus capitis muscle was chosen as a candidate for normalization because it is not known to be affected in JIA; it lies in the center of the FOV and thus is less susceptible to peripheral scan artifacts or motion artifacts; and it can be feasibly included in coronal T1 sequences.

ER2 is preferable to ER1 in that ER2 provides the most favorable ratio of average peak values for symptomatic to asymptomatic joints at 1.73 (1.52/0.88), compared with ER1 1.65 (50.34/30.30) and R 1.4 (2.27/1.6), shows a more favorable ratio of average peak values between symptomatic joints and controls 2.27 (1.52/0.67) compared to R 1.67 (2.27/1.36), and exhibits a slightly more favorable ratio of average peak values between asymptomatic joints and controls 1.3 (0.88/0.67) compared to R, 1.2 (1.6/1.36).

ER2 is preferable to ER1 in that ER2 similar to ER1 discriminates with statistical significance between symptomatic JIA joints and controls at nearly all postgadolinium time points and ER2, unlike ER1, also discriminates with statistical significance between symptomatic and asymptomatic JIA joints beyond 10 minutes, a feasible sampling point for clinical use.

ER2 is preferable to ER1 also in that ER2 provides a longer temporal plateau from 9–13 minutes post injection, compared to ER1 that undergoes a steep upswing during this period (compare Fig 2A to Fig 2E). The long temporal plateau of ER2 is preferable in that it is less susceptible to technical variations in sampling time.

ER2 is preferable to R in that it classifies the TMJ joints better than R. We used the peak ER2 value among control patients over the entire dynamic profile (0.95, patient 9 [right TMJ] at 6 minutes 30 seconds) as a threshold for ER2 and the published 1.55 R threshold.8,6 Using these thresholds, we found that ER2 classified 10/11 symptomatic JIA joints correctly compared with 9/11 joints for R.

ER2 is also conceptually preferable to R in that ER2 is a measure of true synovial enhancement (postgadolinium T1 signal–pregadolinium T1 signal) whereas R reflects the ratio of postgadolinium signal in the synovium to postgadolinium signal in the longus capitis muscle but does not reflect synovial enhancement in the strict sense.

We determined the optimal sampling time to be between 7 minutes 50 seconds and 13 minutes 10 seconds. We studied the average NRs for ER1, ER2, and R over 3 sampling periods, 0–3 minutes 50 seconds; 3 minutes 50 seconds to 7 minutes 50 seconds; and 7 minutes 50 seconds to 13 minutes 10 seconds, reasoning that the most favorable sampling period would be when differences among the NRs for each group were greatest and the profiles exhibited a steady-state or temporal plateau. Our results showed the 7 minute 50 second to 13 minute 10 second periods to be preferable for such.

Our results raise some interesting considerations regarding the effect of medication. For ER2, for example, 3/5 asymptomatic JIA joints (patient 1, left TMJ; patient 2, right TMJ; and patient 6, right TMJ) fell below the control maximum at all sampling time points, thus showing an ER2 consistent with control joints. All 3 of these patients were on antitumor necrosis factor medications at the time of imaging. Two of 5 asymptomatic JIA joints fell above the control threshold, and one of these joints was above the control threshold at all time points, producing a profile curve like that of symptomatic JIA joints. This patient was not on systemic therapy and had no prior exposure to antitumor necrosis factor medications. These preliminary results allow the consideration that asymptomatic joints in patients with JIA behave differently than control joints and are suggestive of a possible normalizing effect of the antitumor necrosis factor medications on NRs that may reflect a therapeutic effect on clinically silent joints in patients with JIA.

Our study provides a robust technique for the quantitative evaluation of synovial enhancement as a biomarker for TMJ synovitis in JIA. Although our patient numbers are low, our data illustrate this method, for which larger numbers of patients would be required for more definitive characterization of enhancement profiles. The study is limited by image resolution. It is not currently feasible to sample the synovia separate from adjacent cartilage and periosteum. The study is limited by heterogeneity of patient treatment regimens. This limitation is nearly unavoidable because only rarely do patients with JIA present initially with TMJ symptoms. A future direction would be to develop a standardized imaging-treatment algorithm to monitor synovial enhancement...
in response to a controlled treatment regimen to understand the pathophysiology of JIA.

Our study is labor intensive in that each joint requires 110 measurements; however, we consider this limitation as a temporary step needed to characterize the temporal enhancement profile of the TMJ so that, in practice, once these profiles are fully characterized, the radiologist may target a particular number of samples and a particular temporal sampling point, for example, from 8–10 minutes post injection.

CONCLUSIONS

We provide a robust, clinically feasible, reproducible, dynamic gadolinium-enhanced technique for the quantitative assessment of TMJ synovitis in JIA. We explored 3 NRs, each of which normalizes the postgadolinium synovial signal to an easily measurable, internal reference and found that ER2 is the preferred equation for the quantitative assessment of synovial inflammation. Our data show the dependency of synovial enhancement on sampling time and the misclassification of joints that may result from sampling time inconsistencies and suggest that the preferred sampling time for synovial enhancement lies between 7 minutes 50 seconds and 13 minutes 10 seconds. We therefore provide what we hope will serve as a platform for the quantitative assessment of TMJ synovitis in JIA and areas for future research.

Disclosures: Zachary S. Peacock—UNRELATED: Grants/Grants Pending: Oral and Maxillofacial Surgery Foundation, AO Foundation, Comments: for research on distraction osteogenesis*; Payment for Lectures Including Service on Speakers Bureau: Ethicon/Depuy Synthes, Comments: provided lecture to Ethicon employees on the use of their products for distraction osteogenesis in June 2016 and received honorarium. Hugh D. Curtin—UNRELATED: Royalties: Elsevier, Comments: royalties for a book. *Money paid to the institution.

REFERENCES

1. Petty RE, Southwood TR, Manners P, et al; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–92 Medline
2. Krause ML, Crowson CS, Michet CJ, et al. Juvenile idiopathic arthritis in Olmsted County, Minnesota, 1960–2013. Arthritis Rheumatol 2016;68:247–54 CrossRef Medline
3. Keller H, Müller LM, Markic G, et al. Is early TMJ involvement in children with juvenile idiopathic arthritis clinically detectable? Clinical examination of the TMJ in comparison with contrast enhanced MRI in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2015;13:56 CrossRef Medline
4. Küseler A, Pedersen TK, Herlin T, et al. Contrast-enhanced magnetic resonance imaging as a method to diagnose early inflammatory changes in the temporomandibular joint in children with juvenile chronic arthritis. J Rheumatol 1998;25:1406–12 Medline
5. Ma GM, Amirabadi A, Inarejos E, et al. MRI thresholds for discrimination between normal and mild temporomandibular joint involvement in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2015;13:53 CrossRef Medline
6. Peacock ZS, Vakilian P, Caruso P, et al. Quantifying synovial enhancement of the pediatric temporomandibular joint. J Oral Maxillofac Surg 2016;74:1937–45 CrossRef Medline
7. von Kalle T, Stuber T, Winkler P, et al. Early detection of temporomandibular joint arthritis in children with juvenile idiopathic arthritis: the role of contrast-enhanced MRI. Pediatr Radial 2015;45:402–10 CrossRef Medline
8. Resnick CM, Vakilian PM, Kaban LB, et al. Quantifying the effect of temporomandibular joint intra-articular steroid injection on synovial enhancement in juvenile idiopathic arthritis. J Oral Maxillofac Surg 2016;74:2363–69 CrossRef Medline
9. Weiss PF, Arabshahi B, Johnson A, et al. High prevalence of temporomandibular joint arthritis at disease onset in children with juvenile idiopathic arthritis, as detected by magnetic resonance imaging but not by ultrasound. Arthritis Rheum 2008;58:1189–96 CrossRef Medline